Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — H1 2020 Earnings Presentation
23 slides from Marinomed Biotech's earnings presentation, Aug 27, 2020
Slide 1: Creating innovative therapies for respiratory, allergy and eye diseases
Creating innovative therapies for respiratory, allergy and eye diseases Investor Presentation H1/2020 Andreas Grassauer, CEO, Pascal Schmidt CFO Vienna, 27th August 2020
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Highlights and News
Highlights and News Marinomed – on the COVID-19 frontline ▪ Pre-clinical data show that Carragelose® has the potential to reduce the risk of an infection with SARS-CoV-2 and may also treat COVID-19 ▪ Study in Argentina shows excellent clinical data with Carragelose® in combination with ivermectin ▪
Slide 4: Carragelose – broad band virus blocker
Carragelose® – broad band virus blocker Carragelose® blocks viral attachment to cells via an unspecific physical mechanism Trapped viruses Preservative-free. Carragelose® Cold viruses bind to leave the body via Colds are caused by Can be used from creates a protective the surfaces of the the natural
Slide 5: Carragelose neutralizes SARS-CoV-2
I. Carragelose® neutralizes SARS-CoV-2 New Data published on July 16th, 2020 Determination of IC50 Neutralization of SARS-CoV-2 pseudotyped virus neg. pos. Iota- pos. control control control carrageenan serum serum The neutralizing effect of Carragelose is comparable to serum from a patient who rece
Slide 6: Carragelose significantly inhibit SARS-CoV-2 replication in tissue culture
II. Carragelose® significantly inhibit SARS-CoV-2 replication in tissue culture New Data published on August 21st from independent group in Argentina/USA SARS-CoV-2 virus replication inhibition (Log10 TD50) SARS-CoV-2 viral titer after treatment with iota carrageenan and P2 (3 replicates per treatme
Slide 7: Study of the efficacy and safety of topical Ivermectine and Iota-carrageenan
Study of the efficacy and safety of topical Ivermectine and Iota-carrageenan Positive data on the prophylaxis of COVID-19 for health care personnel Incidence of Study Group SARS-CoV-2 Intervention participants (PCR) Iota + Ivermectin group topical medication, iota- Iota-carrageenan + carrageenan and
Slide 8: SARS-CoV-2 clinical trial started in Argentina
SARS-CoV-2 clinical trial started in Argentina Investigator initiated trial at: Centro de educación médica e investigaciones clinicas (CEMIC) Instituto Milstein-CONICET Buenos Aires, Capital Federal, Argentina Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disea
Slide 9: Carragelose: safe and available innovation
Carragelose®: safe and available innovation Carragelose® - a new frontrunner in SARS-CoV-2 countermeasures ▪ Carragelose® products – nasal spray, throat spray and lozenges - bear a huge potential in the fight against the Coronavirus ▪ Today, Carragelose® products are marketed in more than 40 countri
Slide 10: Marinomed updated pipeline
Marinomed updated pipeline respiratory respiratory gastrointestinal respiratory 10
Slide 11: Marinosolv explained based on Budesolv
Marinosolv explained based on Budesolv Marinosolv® allows to provide Budesonide in solution offering a competitive edge Suspension Solution Rhinocort Aqua Marinosolv® enabled Budesonide nasal spray Budesonide nasal spray 64µg per dose/spray 10µg per dose/spray Properties USPs Proven Solubility incre
Slide 12: Upcoming milestones and value inflection points
Upcoming milestones and value inflection points… Preliminary Timetable 2019 H2 ▪ Completion of pivotal Phase-III trial for Budesolv ✓ ▪ Establishment of large-scale production for Budesolv ✓ H1 ▪ Grant for €4m project from FFG for fighting COVID-19 ✓ 2020 ▪ Relocation of 1st part of the company to n
Slide 13: Double digit growth
Double digit growth Growth path of Carragelose® maintained in 2020 Y-o-Y comparison of Revenues (in m€) Comments ▪ Double digit growth in revenue was achieved +35% +40% +38% from the sale of products in the Carragelose® segment 2.3 1.7 ▪ First revenues from services provided through 1.3 application
Slide 14: Significant investments into R&D
Significant investments into R&D Planned continued losses through high R&D investments are sufficiently funded R&D Expenses Comments ▪ Significant investments in R&D as planned, primarily relating to R&D personnel expenses and external services for clinical trials 1.4 1.3 1.0 ▪ COVID-19 pandemic res
Slide 15: Supply chain improvements
Supply chain improvements Strong focus on eliminating bottlenecks in supply Comments Inventory ▪ Two main drivers for supply chain improvements: 1. Close collaboration with manufacturing organizations • Improvement of long-term planning to reserve capacity • Become preferred partner to receive produ
Slide 16: Positive Outlook 2020
Positive Outlook 2020 Investments in Marinosolv® and commercialisation of Carragelose® Further strong demand for Carragelose® products expected ▪ Lab data and clinical data for Sars-CoV-2 are growth drivers ▪ Full focus on conversion of data into marketing & sales ▪ Expansion of capacities continues
Slide 17: Stay Healthy!
Stay Healthy! …and further reduce the risk by following these rules + + + Wash Keep Wear Use your hands distance a mask Carragelose® regularly nasal spray 17
Slide 18: Appendix
: Orrarino Appendix : Po
Slide 19: Statement of profit or loss
Statement of profit or loss €m H1 2020 H1 2019 1 Revenue €m H1 2020 H1 2019 Revenues 1 2.3 1.7 Sale of goods 2.0 1.5 License revenues 0.1 0.0 Other income 0.5 0.3 Other revenues 0.1 0.2 Other net gains/losses (0.0) 0.0 Total revenue 2.3 1.7 Materials expenses (1.6) (1.1) Services expenses 2 (1.0) (1
Slide 20: Statement of financial position
Statement of financial position Assets €m H12020 2019 1 Therein fully renovated office building and land in Korneuburg €2.6m (2019: €0.4m) as well as assets Assets under construction €1.1m (2019: €1.8m) related to Intangible assets 1.7 1.6 the laboratory building Property, plant and equipment 1 4.1
Slide 21: Statement of financial position
Statement of financial position Equity and liabilities €m H12020 2019 1 Therein IPO related paid-in capital of €20.3m (net of transaction costs) and conversion of the Equity and liabilities convertible bond in the amount of €13.1m Share capital 1.5 1.5 Capital reserves 2 Primarily related to first t
Slide 22: Statement of cash flows (IFRS)
Statement of cash flows (IFRS) Change in cash position primarily related to loss for the period Net Cash at Net change in Net D&A Cash at beginning Loss for financial working interest and Investing Financing end of of period the period result capital paid other cash flow cash flow period 22
Slide 23: www.marinomed.com
: Orrarino www.marinomed.com